Short Interest in Enfusion, Inc. (NYSE:ENFN) Increases By 14.6%

Enfusion, Inc. (NYSE:ENFN) was the recipient of a large growth in short interest in June. As of June 15th, there was short interest totalling 1,810,000 shares, a growth of 14.6% from the May 31st total of 1,580,000 shares. Based on an average daily volume of 332,700 shares, the days-to-cover ratio is presently 5.4 days. Currently, 3.7% of the shares of the stock are sold short.

Insider Transactions at Enfusion

In related news, insider Bronwen Bastone sold 10,539 shares of the firm’s stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $8.17, for a total transaction of $86,103.63. Following the transaction, the insider now directly owns 217,154 shares of the company’s stock, valued at approximately $1,774,148.18. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Deirdre Somers sold 4,629 shares of the company’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $8.40, for a total transaction of $38,883.60. Following the completion of the transaction, the director now directly owns 43,312 shares of the company’s stock, valued at $363,820.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Bronwen Bastone sold 10,539 shares of the firm’s stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $8.17, for a total value of $86,103.63. Following the completion of the sale, the insider now directly owns 217,154 shares in the company, valued at $1,774,148.18. The disclosure for this sale can be found here. In the last three months, insiders sold 36,318 shares of company stock worth $296,688. 36.44% of the stock is currently owned by corporate insiders.

Institutional Trading of Enfusion

Several large investors have recently added to or reduced their stakes in ENFN. Brown Capital Management LLC lifted its position in shares of Enfusion by 6.5% during the 4th quarter. Brown Capital Management LLC now owns 11,817,661 shares of the company’s stock valued at $114,631,000 after buying an additional 724,502 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Enfusion by 17.2% in the third quarter. Vanguard Group Inc. now owns 3,487,815 shares of the company’s stock worth $31,286,000 after purchasing an additional 512,479 shares during the period. Scalar Gauge Management LLC purchased a new stake in shares of Enfusion in the fourth quarter worth $1,993,000. Wasatch Advisors LP raised its position in shares of Enfusion by 34.2% during the 1st quarter. Wasatch Advisors LP now owns 792,083 shares of the company’s stock valued at $7,327,000 after purchasing an additional 201,771 shares during the period. Finally, Hudson Bay Capital Management LP lifted its stake in shares of Enfusion by 29.7% during the 3rd quarter. Hudson Bay Capital Management LP now owns 460,084 shares of the company’s stock valued at $4,127,000 after buying an additional 105,236 shares in the last quarter. 81.05% of the stock is currently owned by institutional investors.

Enfusion Stock Up 1.1 %

ENFN traded up $0.09 during mid-day trading on Wednesday, reaching $8.51. 10,554 shares of the company traded hands, compared to its average volume of 376,286. The company’s fifty day moving average price is $9.04 and its 200-day moving average price is $9.03. The stock has a market capitalization of $1.09 billion, a P/E ratio of 280.93, a P/E/G ratio of 1.98 and a beta of 0.92. Enfusion has a 52-week low of $7.52 and a 52-week high of $11.56.

Enfusion (NYSE:ENFN) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). The firm had revenue of $48.05 million for the quarter, compared to analysts’ expectations of $47.67 million. Enfusion had a net margin of 1.40% and a return on equity of 6.60%. During the same quarter last year, the company posted $0.04 EPS. As a group, sell-side analysts forecast that Enfusion will post 0.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on ENFN shares. Bank of America lifted their price target on shares of Enfusion from $8.00 to $9.00 and gave the company an “underperform” rating in a research report on Wednesday, March 13th. Morgan Stanley assumed coverage on Enfusion in a research note on Friday, May 10th. They set an “overweight” rating and a $11.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $9.33.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.